Risk Breakdown
Financial Exposure
Governance
Double Materiality
Supply Chain
Material Risks
ESG Targets & Commitments
| Topic | Target / Metric | Status |
|---|---|---|
| Human Rights in Supply Chain | HR clauses in all contracts | Commitment |
AI Risk Summary
# Financial Risk Summary: Alkem Laboratories Limited Alkem faces its largest financial exposure through **compliance risk (10.0/10 score) and EPR liability (6.5/10)**, with estimated remediation costs of ₹17–63 crore—representing 0.16–0.60% of annual revenue. The company's critical gap is missing emissions data (Scope 1 & 2 reported as "None"), which creates immediate SEBI BRSR non-compliance risk under the Core Expansion mandate, potentially triggering enforcement action and delisting for top-tier listing status. EPR applicability remains undetermined for pharmaceutical/nutraceutical packaging, leaving contingent liability exposure unquantified; once clarified under Extended Producer Responsibility regulations, Alkem could face additional collection and recycling obligations. Priority action required: establish verified GHG accounting, clarify EPR applicability with regulators, and complete compliance roadmap within 6–12 months to mitigate reputational and capital market sanctions.
Source: Alkem Laboratories Limited BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.